about
The role of the SCN5A-encoded channelopathy in irritable bowel syndrome and other gastrointestinal disordersLoss-of-Function of the Voltage-Gated Sodium Channel NaV1.5 (Channelopathies) in Patients With Irritable Bowel SyndromeNonantithrombotic medical options in acute coronary syndromes: old agents and new lines on the horizon.Ranolazine: a new approach to treating an old problem.Modulating fatty acid oxidation in heart failure.Ranolazine inhibits voltage-gated mechanosensitive sodium channels in human colon circular smooth muscle cells.Cancer metabolism: fatty acid oxidation in the limelight.Controversies in cardiovascular medicine: Chronic stable coronary artery disease: drugs vs. revascularization.PHD3 Loss in Cancer Enables Metabolic Reliance on Fatty Acid Oxidation via Deactivation of ACC2.Overview of Management of Myocardial Ischemia: a Mechanistic-Based Approach.Ranolazine selectively blocks persistent current evoked by epilepsy-associated Naν1.1 mutations.Influence of quercetin on the pharmacokinetics of ranolazine in rats and in vitro models.Clinical experience with ranolazine in a veteran population with chronic stable angina.Voltage-gated sodium channels: (NaV )igating the field to determine their contribution to visceral nociception.Irritable bowel syndrome (IBS) patients have SCN5A channelopathies that lead to decreased NaV1.5 current and mechanosensitivity.Treating stable angina - is there a NICE way towards an international consensus?
P2860
Q28081627-B50D55DE-C8D2-4BA8-8DE5-49C19B934A20Q29544671-57742873-E38D-4E96-A31C-5952B632F0B9Q30583012-A56256C0-4997-43DA-8A07-E4DA17B034B5Q34457675-381A2C3B-C731-4BE5-8AD2-B1D25AECF0F6Q34808505-EF4C6FCC-DE67-4DDE-A389-CCA8FA3FF706Q36066445-EFA4AC5A-7B04-4E77-A355-126C84772688Q37155867-7D9516DA-F7B1-45F0-864F-90DDAF49B3C6Q37682501-8459039A-5B4C-4CF0-817F-4B38991A636BQ38745971-3F231D0E-D9BC-429C-BBBA-CAABD59387DFQ38811072-38BFA5D4-064F-4A13-B485-CD2D7808216FQ41121995-04F5F675-EBF0-446A-8214-C81B9FA159FFQ44451449-BA8BD9AB-C923-4197-9CC8-4F7332670320Q45330316-04D4FF55-F5A6-498C-A3C1-911940A67DCAQ48273674-7FF68932-C202-4778-B5CF-AC4F8A3EF8B2Q49789569-E76F6E1D-2C6B-4341-B65F-6AC6675365E8Q53128488-255715AB-EE10-49FA-88B0-98147C5D2388
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Ranolazine for chronic stable angina.
@en
Ranolazine for chronic stable angina.
@nl
type
label
Ranolazine for chronic stable angina.
@en
Ranolazine for chronic stable angina.
@nl
prefLabel
Ranolazine for chronic stable angina.
@en
Ranolazine for chronic stable angina.
@nl
P1433
P1476
Ranolazine for chronic stable angina.
@en
P2093
David T Nash
Stephen D Nash
P304
P356
10.1016/S0140-6736(08)61554-8
P407
P577
2008-10-01T00:00:00Z